IL5 and asthma: Patients with severe asthma treated with omalizumab and anti-IL-5 biologics frequently experienced subsequent annual AEs and SAEs after the entry in the FeNOhi/B-EOSlo subgroup, compared with the other FeNO/B-EOS subgroups (Supplementary Figure S3), suggesting that these biologics were partially effective in the FeNOhi/B-EOSlo subgroups.